Your Global Leader in Stem Cell Market Research
Over the past decade, CAR-T cell therapies have revolutionized the field of cell therapy, demonstrating clear curative potential with autologous approaches. Now, the field is looking to take these treatments a step further, by delivering next generation products that are cheaper, safer, and more efficacious. [Read more…]
While there has been a consistent stream of RMAT approvals since the designation was created in 2017, with 60 publicly announced to date, the number of approvals in the first few days in 2022 are noteworthy. Specifically, from January 1 to January 18, 2022, four companies publicly announced RMAT designations, as described below.
An RMAT designation is an award from the U.S. FDA that allows for faster, more streamlined approvals of regenerative medicine products within the United States, such as cell and gene therapies, tissue engineering products, and combination products. RMAT designations make innovative products eligible for quicker development and review of a marketing application. [Read more…]
Cord tissue banking is the processing and storage of a newborn’s umbilical cord tissue or the components contains, such as Wharton’s jelly. Wharton’s jelly is a thick, gelatinous substance present within the human umbilical cord that contains a range of important cell types, such as mesenchymal stem cells (MSCs), fibroblasts and macrophages.
In this article:
CAR-T is a promising type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the capacity to recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.”
Since the approval of the first CAR-T cell therapeutic in 2017, widespread research, proliferating clinical trials, aggressive M&A activity, and lucrative IPOs have created a robust CAR-T cell market. [Read more…]
